Teduglutide, a glucagon-like peptide-2 analogue (REVESTIVE), in the treatment of short bowel syndrome with dependence  on home parenteral nutrition

Česká verze

Authors: Novák F.
Authors place of work: 1. LF UK a IV. interní klinika VFN v Praze
Published in the journal: Gastroent Hepatol 2021; 75(2): 170-172
Category: Lékový profil
doi: https://doi.org/10.48095/ccgh2021170

Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012; 143(6): 1473–1481. doi: https://doi.org/10.1053/j.gastro.2012.09.007.
Schwartz LK, O’Keefe SJD, Fujioka K et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol 2016; 7(2): e142. doi: 10.1038/ctg.2015.69.
Jeppesen PB, Gilroy R, Pertkiewicz M et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011; 60: 902–914. doi: 10.1136/gut.2010.218271.
O’Keefe SJD, Jeppesen PB, Gilroy R et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol 2013: 11: 815–823. doi: 10.1016/j.cgh.2012.12.029.
Společné stanovisko VZP ČR a SKVIMP ČLS JEP. 2020 [online]. Dostupné z: https://media.vzpstatic.cz/media/Default/dokumenty/spolecna-stanoviska/2020_06_10_spolecne-stanovisko_lp-revestive.pdf.
Wohl P, Šenkyřík M, Těšínský P et al. Konsenzus odborníků v léčbě SBS. 2019 [online]. Dostupné na: http://www.skvimp.cz/soubory/Advisory-Board-Revestive-Consensus-Praha-14.10.2019.pdf.